Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress
Stock Information for Akari Therapeutics Plc
Loading
Please wait while we load your information from QuoteMedia.